Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Overall, the collective findings from this Phase 1b clinical trial provide the Company with strong confidence that LTI-03 has ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

马萨诸塞州沃尔瑟姆 - 生物制药公司Aileron Therapeutics, Inc. (NASDAQ: ALRN)宣布了其针对特发性肺纤维化(IPF)的新型治疗候选药物LTI-03的1b期临床试验第二组队列的积极结果。该试验评估了吸入型LTI-03（一种与Caveolin-1相关的肽）在IPF患者中的安全性和药效学特性。 试验显示,在给予高剂量LTI-03(5 mg BID)后,8个IPF生物 ...

Panagiotis Tarinidis has unofficially exceeded the U66KG IPF Raw Total World Record with a score of 713 kilograms (1,571.9 ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

“A highlight to this quarter’s progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is ...